ToPanc Trial: Survival After Total Versus Partial Pancreaticoduodenectomy for Adenocarcinoma of the Pancreatic Head, Distal Cholangiocarcinoma, and Ampullary Cancer

Last updated: September 29, 2025
Sponsor: Insel Gruppe AG, University Hospital Bern
Overall Status: Active - Recruiting

Phase

N/A

Condition

Digestive System Neoplasms

Liver Cancer

Biliary Tract Cancer

Treatment

Partial pancreaticoduodenectomy (PD)

Total pancreatectomy (TP)

Clinical Study ID

NCT06801899
2024-02010
  • Ages > 18
  • All Genders

Study Summary

The goal of this clinical trial is to learn if total removal of the pancreas is a preferable alternative to partial removal in patients with cancer of the pancreatic head who are at high risk of pancreatic leakage. The main question it aims to answer is:

Does total pancreas removal improve survival without reducing quality of life compared to partial removal?

The only study specific procedures are the collection of 2 blood samples (7.5ml for each time point, preoperatively and during the hospitalisation) and the completion of the questionnaires.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Adult patients (age ≥ 18 years) scheduled to undergo PD for highly suspected orhistologically proven, resectable pancreatic ductal adenocarcinoma (PDAC), distalcholangiocarcinoma (DCC), and/or ampullary cancer (pancreaticobiliary type)

  • Suspected pancreas anastomosis at high-risk for development of a postoperativepancreatic fistula (POPF) (grade "D" according to Schuh et al. (29): Estimation byCT scan, MRI, and/or Endoscopic Ultrasound

  • Written informed consent

Exclusion

Exclusion Criteria:

  • Duodenal carcinoma, ampullary cancer (intestinal type), neuroendocrine tumors,benign tumors, chronic pancreatitis

  • Medical conditions that do not allow appreciation of the nature, scope, and possibleconsequences of the trial as judged by the investigator

  • Pregnancy. A beta-Human Chorionic Gonadotropin (bHCG) pregnancy test must to beperformed for women of child-bearing potential (defined as premenopausal women whohave not undergone surgical sterilization)

  • Inability to follow the study procedures, e.g., due to psychological disorders,dementia, etc.

Study Design

Total Participants: 170
Treatment Group(s): 2
Primary Treatment: Partial pancreaticoduodenectomy (PD)
Phase:
Study Start date:
May 12, 2025
Estimated Completion Date:
July 31, 2029

Study Description

The pancreas is located in the upper abdomen and has 2 main functions: Production of digestive juices and of insulin, the latter being most important for blood sugar regulation and energy conservation. Certain types of cancer in the pancreatic head are very aggressive, but with complete surgical removal of the tumor and additional chemotherapy cure is possible. For tumor resection, the head of the pancreas as well as duodenum and part of the bile duct are removed. 3 new connections are built: the remaining pancreas, bile duct and stomach are connected to a loop of small intestine.

This operation takes around 6 hours and leads to complications in 20-30% of cases. A serious complication and unfortunately the most frequent is the leaking of the pancreas remnant, with outflow of the aggressive digestive juice into the surrounding tissue. Consequences may be severe bleeding and/or infections. Many studies show that affected patients have an increased risk of tumor recurrence and a reduced survival.

To avoid pancreatic leak, the entire pancreas can be removed. So far, removal of the whole pancreas has only been chosen in cases of very advanced cancer. After both, partial or total pancreas removal, patients need to substitute digestive enzymes. This can be done by capsules, which need to be taken with every meal. But while some patients after partial removal maintain sufficient function to produce insulin, all patients after total removal are diabetic and need insulin injections. In the past, blood sugar control in the absence of insulin production was difficult and accompanied by low quality of life (QoL). This has changed tremendously by the introduction of continuous glucose monitoring (sensors, which are attached to the arm) and automated insulin delivery systems (also known as "artificial pancreas"). This development renders total pancreas removal a reasonable alternative, with the advantage, that only 2 new connections are made: One between the bile duct and small intestine and one between the stomach and the small intestine.

Study question: Is removal of the whole pancreas in patients at high risk of a pancreatic leakage a preferable alternative to partial removal?

For this study, patients with cancer of the pancreatic head who are planned for surgery can be included. These patients will be randomly assigned to two groups:

  1. Standard group: partial removal of the pancreas

  2. Study group: total removal of the pancreas

Both techniques are safe and are established techniques to treat cancer in the pancreatic head. After the operation, many clinical data will be recorded. The two most important factors will be survival and quality of life, which will be assessed by questionnaires on a regular base. Additionally, postoperative complications, chemotherapy rates, tumor recurrence and many more data will be monitored.

Connect with a study center

  • Department of Surgery, Kantonsspital Baden

    Baden, 5404
    Switzerland

    Site Not Available

  • Department of Surgery, Kantonsspital Baden

    Baden 2661646, 5404
    Switzerland

    Active - Recruiting

  • Department of Visceral Surgery, University Hospital Basel

    Basel, 4031
    Switzerland

    Site Not Available

  • Department of Visceral Surgery, University Hospital Basel

    Basel 2661604, 4031
    Switzerland

    Site Not Available

  • Inselspital, Bern University Hospital

    Bern, 3010
    Switzerland

    Site Not Available

  • Inselspital, Bern University Hospital

    Bern 2661552, 3010
    Switzerland

    Active - Recruiting

  • Department of Visceral Surgery, University Hospital Geneva

    Geneva, 1205
    Switzerland

    Site Not Available

  • Department of Visceral Surgery, University Hospital Geneva

    Geneva 2660646, 1205
    Switzerland

    Active - Recruiting

  • Department of General, Visceral, Endocrine and Transplantation Surgery, Kantonsspital St. Gallen

    Saint Gallen, 9000
    Switzerland

    Site Not Available

  • Department of General, Visceral, Endocrine and Transplantation Surgery, Kantonsspital St. Gallen

    Sankt Gallen 2658822, 9000
    Switzerland

    Active - Recruiting

  • Department of Surgery and Transplantation, University Hospital Zürich

    Zurich 2657896, 8091
    Switzerland

    Active - Recruiting

  • Department of Surgery, Stadtspital Triemli Zürich

    Zurich 2657896, 8063
    Switzerland

    Site Not Available

  • Department of Surgery and Transplantation, University Hospital Zürich

    Zürich, 8091
    Switzerland

    Site Not Available

  • Department of Surgery, Stadtspital Triemli Zürich

    Zürich, 8063
    Switzerland

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.